Bell J Simon, Klaukka Timo, Ahonen Jouni, Hartikainen Sirpa
Kuopio Research Centre of Geriatric Care, University of Kuopio, Kuopio, Finland.
Am J Geriatr Pharmacother. 2009 Dec;7(6):355-61. doi: 10.1016/j.amjopharm.2009.11.006.
The use of opioids has increased rapidly in Europe and North America, and older people may be susceptible to opioid-related adverse drug events. The Finnish National Agency for Medicines has recommended that oral opioids be considered the first-line treatment when a strong opioid is required for severe pain.
The objective of this study was to investigate and describe the age-, indication-, sex-, and geographic-specific utilization of transdermal fentanyl among older people residing in noninstitutional settings in Finland.
Reimbursement data for fentanyl, morphine, oxycodone, and hydromorphone were extracted from the Finnish National Prescription Register for 2008. Age-specific population data were used to calculate the annual prevalence of opioid use for malignant and nonmalignant pain for patients aged < or = 64, 65 to 69, 70 to 74, 75 to 79, 80 to 84, 85 to 89, 90 to 94, 95 to 99, and >99 years. The annual prevalence of transdermal fentanyl use was also calculated separately for each of the 21 hospital districts in Finland.
Reimbursement for transdermal fentanyl was paid to 2746 people for malignant pain and 6223 people for nonmalignant pain. The annual prevalence of transdermal fentanyl use for nonmalignant pain was lowest among men aged < or = 64 years (2.2 users/10,000 men) and highest among women >99 years (539.2 users/10,000 women). The annual prevalence of transdermal fentanyl use was >47 times higher than that of morphine for nonmalignant pain among people aged 85 to 89 years and >97 times higher than that of morphine among people aged 90 to 94 years. A greater than 4-fold variation in the annual prevalence of transdermal fentanyl use was reported among the 21 hospital districts in Finland (range, 9.5-40.6/10,000 inhabitants).
The prevalence of transdermal fentanyl use was higher than that of morphine, oxycodone, and hydromorphone among people aged > or = 80 years residing in noninstitutional settings in Finland. The variation in use between hospital districts suggests that organizational culture may have a strong impact on prescribing practices. Our data highlight the need for further education regarding the appropriate use of opioids among older people.
在欧洲和北美,阿片类药物的使用迅速增加,老年人可能易发生与阿片类药物相关的不良药物事件。芬兰国家药品管理局建议,当严重疼痛需要强效阿片类药物时,口服阿片类药物应被视为一线治疗药物。
本研究的目的是调查并描述芬兰非机构环境中老年人经皮芬太尼在年龄、适应证、性别和地域方面的使用情况。
从芬兰国家处方登记处提取2008年芬太尼、吗啡、羟考酮和氢吗啡酮的报销数据。使用特定年龄的人口数据计算年龄小于或等于64岁、65至69岁、70至74岁、75至79岁、80至84岁、85至89岁、90至94岁、95至99岁以及大于99岁的患者因恶性和非恶性疼痛使用阿片类药物的年患病率。还分别计算了芬兰21个医院辖区经皮芬太尼使用的年患病率。
2746人因恶性疼痛、6223人因非恶性疼痛获得了经皮芬太尼报销。经皮芬太尼用于非恶性疼痛的年患病率在年龄小于或等于64岁的男性中最低(每10000名男性中有2.2名使用者),在年龄大于99岁的女性中最高(每10000名女性中有539.2名使用者)。85至89岁人群中经皮芬太尼用于非恶性疼痛的年患病率比吗啡高47倍以上,90至94岁人群中比吗啡高97倍以上。芬兰21个医院辖区经皮芬太尼使用的年患病率报告存在4倍以上的差异(范围为每10000名居民中9.5 - 40.6名使用者)。
在芬兰非机构环境中,年龄大于或等于80岁的人群中经皮芬太尼的使用患病率高于吗啡、羟考酮和氢吗啡酮。医院辖区之间使用情况的差异表明组织文化可能对处方行为有很大影响。我们的数据突出了对老年人进行阿片类药物合理使用进一步教育的必要性。